Patients diagnosed with stage III or IV periodontitis who exhibit mandibular first or second molars with Class II, Subclass A, or B buccal and/or lingual mandibular furcation defects (horizontal probing depth of ≥ 3 mm ) will be recruited. Patients diagnosed with stage III or IV periodontitis who exhibit maxillary first or second molars with Class II, Subclass A, or B buccal furcation defects (horizontal probing depth of ≥ 3 mm ) if furcation involvement on the palatal side (mesiopalatal and distopalatal) does not exceed Class 1 will be recruited. This study will be a prospective, randomized, single-blinded, controlled clinical trial with a split-mouth design. Patients will be recruited from the clinics of the Riga Stradiņš University Institute of Stomatology of Riga, Latvia. Before the baseline treatment, all patients who meet the inclusion criteria will be given detailed oral hygiene instructions and motivation. Patients' furcation defects in each quadrant will be randomly allocated at a 1:1 ratio to either the application of Oscillating Chitosan Brush with Enamel Matrix Derivatives (test group) or Oscillating Chitosan Brush alone (control group). Non-surgical periodontal treatment of furcation defects on the test side will be performed through the application of Oscillating Chitosan Brush with Enamel Matrix Derivatives and on the control side with Oscillating Chitosan Brush alone. The re-evaluation of periodontal status will be performed 12 weeks following the baseline treatment. Biofilm samples and gingival crevicular fluid (GCF) samples will be taken at the baseline and at 4 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
40
Enamel Matrix Derivatives
Oscillating Chitosan Brush
Riga Stradins University Institute of Stomatology
Riga, Latvia
RECRUITINGModified Bleeding on Probing index (mBoP)
Pseudo marker of inflammation, lower scores mean a better outcome 0 = no bleeding; 1. = a bleeding spot; 2. = a bleeding line; 3. = pronounced bleeding within 30 seconds following probing of the pocket
Time frame: Baseline, 12 weeks
Probing Pocket Depth (PPD) in mm
Pseudo marker of inflammation, lower scores mean a better outcome.
Time frame: Baseline,12 weeks
Clinical Attachment Level (CAL) in mm
Marker of gain in attachment, lower scores mean a better outcome
Time frame: Baseline, 12 weeks
Furcation Involvement 1
Marker of gain in attachment, Horizontal Furcation involvement measurement using Nabers Probe 1. Horizontal loss of periodontal tissue support less than 3 mm 2. Horizontal loss of support 3 mm or more, but not encompassing the total width of the furcation 3. Horizontal through-and-through destruction of the periodontal tissue in the furcation Lower scores mean a better outcome
Time frame: Baseline, 12 weeks
Furcation Involvement 2 in mm
Marker of gain in attachment, Horizontal Furcation involvement measurement using UNC 15mm probe, lower scores mean a better outcome
Time frame: Baseline, 12 weeks
Proteomic profile of gingival crevicular fluid (GCF)
Differences in the GCF of regeneration-related marker concentrations between test and control groups
Time frame: Baseline, 4 weeks,
Microbiological changes in microbial plaque
Differences in the microbial profile between test and control groups
Time frame: Baseline, 4 weeks,
Visual analog scale (VAS)
Evaluation of self-perceived pain using a 100 mm Visual analog scale (range 0 - 100) at baseline treatment visit; 0 - no pain, 100 - worst pain ever felt. Lower scores mean a better outcome.
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.